|
|
Article: Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX[R] Varenicline Compared With Placebo.
- Article from:
- Vaccine Weekly
- Article date:
- November 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX[R] (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p
"Quitting smoking is of paramount importance for all smokers, particularly those with a smoking-related illness, such as COPD," said Dr. Donald Tashkin, study investigator, emeritus professor of medicine at University of California, Los Angeles. "This study shows that varenicline is an effective means of smoking cessation for a highly nicotine-dependent, ...